Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230464 | 0.84 | POLB (0.37) | NPC1POLBALDH1A1PHGDHMGLL | |
| SCHEMBL2230403 | 0.73 | ABCB1 (0.32) | — | |
| SCHEMBL15598959 | 0.70 | — | — | |
| Methyl Alcohol SCHEMBL11197540 | 0.69 | NPC1 (0.48) | NPC1 | |
| SCHEMBL6381815 | 0.68 | NPC1 (0.52) | NPC1 | |
| SCHEMBL190984 | 0.68 | NPC1 (0.52) | NPC1 | |
| SCHEMBL9129950 | 0.68 | NPC1 (0.52) | NPC1 | |
| SCHEMBL9128685 | 0.68 | NPC1 (0.52) | NPC1 | |
| SCHEMBL17885048 | 0.68 | NPC1 (0.52) | NPC1 | |
| SCHEMBL6383373 | 0.68 | NPC1 (0.52) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102177125-B | Process for producing alpha-hydroxyketone compound | SUMITOMO CHEMICAL CO | 2013-10-30 | — | — | CN | disclosed |
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
| CN-103159653-A | Method for producing methionine | SUMITOMO CHEMICAL CO | 2013-06-19 | — | — | CN | disclosed |
| US-20130150611-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| CN-103080064-A | Process for producing carboxylic acid ester | SUMITOMO CHEMICAL CO | 2013-05-01 | — | — | CN | disclosed |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-03-21 | — | — | US | disclosed |
| US-8350051-B2 | Process for producing alpha-hydroxyketone compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-08 | — | — | US | disclosed |
| CN-102177125-A | Process for producing alpha-hydroxyketone compound | SUMITOMO CHEMICAL CO | 2011-09-07 | — | — | CN | disclosed |
| US-20110178309-A1 | PROCESS FOR PRODUCING ALPHA-HYDROXYKETONE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178309-A1 | PROCESS FOR PRODUCING ALPHA-HYDROXYKETONE COMPOUND | BCKDK, PDK4, HK1 | NPC1 2713/4885POLB 1435/4885DPP4 2104/4885 |
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MSMO1, MGMT | NPC1 3887/4885POLB 214/4885DPP4 2964/4885 |
| US-20130072713-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MGMT, BBOX1 | NPC1 3601/4885POLB 535/4885DPP4 2707/4885 |
| US-20130150611-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | ADH5, ADH1A, ADH1C | NPC1 3528/4885POLB 2095/4885DPP4 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.